Swiss-headquartered plasma products company specializing in coagulation factor therapies (wilate, Nuwiq) for hemophilia and von Willebrand disease, with operations across 40+ countries.
Company Info
Upcoming Milestones & Key Dates
Pediatric wilate label expansion rollout in EU and US
Expected FDA review of additional Nuwiq indication
Clinical Development Pipeline
Recent News
Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years (reported by PR Newswire)
Leadership Team
Chairman and Chief Executive Officer
Chief Financial Officer
Head of Operations
Careers & Job Openings